pascal coquerelle

Dr. pascal coquerelle

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Infectious Diseases Now
Verified
Journal Article
Closed access
MLM. Lacasse
M. Lacasse
SDS. Derolez
S. Derolez
EBEric BONNET
Eric BONNET
AAA. Amelot
A. Amelot
BBB. Bouyer
B. Bouyer
VZValerie Zeller
Valerie Zeller

1 January 2007 in Joint Bone Spine
Verified
Journal Article
Closed access
VDVincent Ducoulombier
Vincent Ducoulombier
ESElisabeth Solau
Elisabeth Solau
PCpascal coquerelle
pascal coquerelle
ÉHÉric Houvenagel
Éric Houvenagel
JSJean-Louis Siame
Jean-Louis Siame
RFRené-Marc Flipo
René-Marc Flipo

7 April 2022 in Rheumatology International
Verified
Journal Article
Open access
PDF file
MRMalory Rodère
Malory Rodère
Bruno PereiraBruno Pereira
Bruno Pereira
MSMartin Soubrier
Martin Soubrier
FFFrançoise FAYET
Françoise FAYET
MPMuriel Piperno
Muriel Piperno
CBCatherine Beauvais
Catherine Beauvais
To develop and validate a questionnaire assessing patient knowledge in rheumatoid arthritis (RA). Knowledge considered essential for patients with RA was identified through a series of Delphi rounds among rheumatologists, health professionals (HPs), patients, and then reformulated to construct the knowledge questionnaire. Cross-sectional multicenter validation was performed in 12 rheumatology departments to assess internal validity (Kuder–Richardson coefficient), external validity, acceptability, reproducibility (Lin’s concordance correlation coefficient) and sensitivity to change (difference in total score before and after patient education sessions). Associations between patient variables and knowledge levels were evaluated. RAKE (RA Knowledge questionnairE) is a self-administered 45-item questionnaire scored 0–100, with a 32-item short-form survey assessing knowledge of disease, comorbidity, pharmacological treatments, non-pharmacological treatments, self-care and adaptative skills. Of 130 patients included in the validation study, 108 were women. Acceptability was good with < 5% missing data. Internal validity coefficient was 0.90. Mean (standard deviation) long-form score was 72.8 ± 17.8, with lower scores in comorbidity and self-care and higher scores in adaptive skills. Reproducibility was good (0.86 [0.80; 0.92]). RAKE score was positively correlated with the patients’ level of education and the HPs’ opinion on the patients’ knowledge. RAKE score showed good sensitivity to change: 66.8 ± 16.4 then 83.8 ± 12.7, representing a hedges effect size of 1.14 [95% CI 0.73; 1.55]. RAKE is an updated questionnaire assessing essential knowledge for patients with RA to enhance self-management according to current guidelines and the patients’ perspective. RAKE can usefully inform patient education interventions, routine care and research.

Verified
Journal Article
Open access
PDF file
JSJean Hugues Salmon
Jean Hugues Salmon
JLJean-Guillaume Letarouilly
Jean-Guillaume Letarouilly
Vincent GoebVincent Goeb
Vincent Goeb
LKLukshe Kanagaratnam
Lukshe Kanagaratnam
PCpascal coquerelle
pascal coquerelle
RFRené-Marc Flipo
René-Marc Flipo
Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi-center study from January 2008 to July 2016, based on the French-RIC Network. We defined three groups of patients followed up for rheumatoid arthritis (RA), according to the date of initiation of ABA therapy: Group 1 (from 2007 to 31 July 2010: ABA indicated after anti-TNF failure); Group 2 (from 1 August 2010 to 31 March 2014: ABA indicated after conventional antirheumatic drugs failure); Group 3 (from 1 April 2014 to 1 July 2016: ABA available by the subcutaneous injection). Results: Among 517 patients who initiated ABA, drug persistence at 12 months was 68%. The only factor significantly associated with persistence rate at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation (odds ratio (OR) 0.6, 95% confidence interval 0.3–0.9; p = 0.0016). There was no significant difference in drug persistence according to date of initiation, the line of biological disease-modifying antirheumatic drugs (bDMARD) therapy or the route of administration. Conclusions: In routine practice, over time, ABA has come to be initiated earlier in the course of therapy for RA in France. Abatacept persistence is similar to that reported in the Orencia Rheumatoid Arthritis (ORA) registry, and does not differ according to the date of initiation. The only factor found to be associated with the persistence rate at 12 months was CRP < 10 mg/L at ABA initiation.

22 November 2023 in Joint Bone Spine
Verified
Journal Article
Closed access
CDChristelle Darrieutort-Laffite
Christelle Darrieutort-Laffite
GCGuillaume Coiffier
Guillaume Coiffier
FAFlorence Aïm
Florence Aïm
FBFréderic Banal
Fréderic Banal
GBGéraldine Bart
Géraldine Bart
SCSalliot carine
Salliot carine

1 June 2019 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
KNK. Nguyen
K. Nguyen
PCpascal coquerelle
pascal coquerelle
Olivier RobineauOlivier Robineau
Olivier Robineau
Eric SennevilleEric Senneville
Eric Senneville